For investors
One wearable brain. A body of add-ons that act on what it knows. A product line that grows by adding, never by starting over.
HemiLogic is a pre-clinical wearable neurotechnology company in Cincinnati. This page is the thesis in its shortest honest form. The full overview is available under NDA.
The thesis
Neurological wearables have failed on two axes. We are building on both.
The first axis is signal. Neurological states are graded, noisy and individual. Devices tuned to binary thresholds either raise false alarms or miss events, and clinicians stop trusting them within weeks. The second axis is accountability. The models that do perform well are opaque, which means no clinician can defend acting on them and no regulator should let them.
Our inference engine is built on fuzzy logic. It handles graded states natively and produces every output as a readable rule with a stated confidence. That is not a feature layered on for compliance. It is the architecture, and it is the reason a clinician, a regulator and a payer can each see why the device did what it did.
The engine lives inside the HemiSense Array: eleven sensors at seven sites, bilateral on the limbs, reading neural, motor and autonomic signals. The array is the product and the brain of the system. Worn alone it detects, monitors and predicts. HemiAct add-ons plug into it and carry out the fourth function, treatment: a counter-signal to a muscle, an adaptive dose, a command to another device.
That is the platform claim. One brain, a growing body, and a sequence of add-ons that share everything below the rule base. Adding an indication means adding a sensor site and a rule base. Adding a product means adding an add-on. Neither means starting over.
Why now
The condition is the largest disease burden on Earth, and the standard of care is still episodic.
We are careful with market language on a site clinicians also read. The overview shared under NDA carries the indication analysis, the addressable population figures with sources, and the regulatory pathway by indication and risk class.
Where we are
Pre-clinical, with the architecture defined and the first product designed.
Now
Bench and archive
Engine development and evaluation against public and partner neurological datasets. Elbow and wrist sites and the SureHand sleeve designed. The other five sites follow.
Next
Feasibility
Prototype hardware and signal quality testing with clinical partners under IRB oversight. Outcome measures co-designed with movement disorder clinicians.
Then
Clinical study
Prospective evaluation of SureHand against accepted clinical reference standards in the lead indication.
Later
Regulatory
Submission pathway determined by indication, claim and risk classification. Second indication begins as a rule base on the same array.
Defensibility
What is hard to copy.
The engine
Explainable fuzzy inference for graded physiological states is the founder's research lineage, with peer-reviewed work through Springer, the ACL and ECCV. It is the part of the stack that cannot be bought off a shelf.
The array
Seven sites, three modalities, one interpretation layer, and an add-on interface that lets the same brain drive a sleeve today and other devices later. The platform economics come from the fact that indications two through four reuse it almost entirely.
The posture
Explainability designed in from the first prototype, not retrofitted for a submission. Regulators and payers are moving toward requiring it. We started there.
What we are raising for
Getting SureHand to a first study, and the platform to its second indication.
- Prototype hardware for the elbow and wrist sites and the woven sleeve
- Feasibility study with a clinical partner in movement disorders
- Regulatory strategy and pre-submission engagement
- Rule base development for the second indication, and the next sensor site, on the existing array
- Embedded and signal processing engineering hires
What we will not say here. Return expectations, valuation, or growth projections. Those belong in a conversation, with the numbers in front of both of us, not on a public page that patients also read.
Request the overview.
Architecture, indication analysis, development plan and regulatory path, shared with qualified investors under NDA.